옵션 체인은 다양한 행사가격과 만기일에 대한 Vital Healthcare Prop Tr의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Vital Healthcare Prop Tr에 대한 시장 심리를 평가합니다..

Vital Healthcare Prop Tr (OTC:VTHPF) 주식, 옵션 체인

Vital Healthcare Property Trust is a healthcare REIT. The vast majority of revenue is generated in Australia, followed by New Zealand. Majority of the company's tenants are for-profit hospitals, followed by medical consultants and nonprofit hospitals. The company's principal activity is the investment in, and management of, high quality real estate in good locations used by healthcare operators or used for healthcare, life sciences and related purposes. It operates in Australia and New Zealand.

VITAL HEALTHCARE PPTY TR by Vital Healthcare Property Trust

Vital Healthcare Property Trust

CrowdStrike Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) shares are trading higher Wednesday. Concerns over potential Iranian cyberattacks may have pushed investor interest <a href="https://www.benzinga.com/news/politics/25/06/46088581/federal-reserve-on-alert-amid-potential-iranian-cyberattack-threats-says-jerome-powell-its-a-big-issue">toward cybersecurity stocks.</a>
What To Know: The move follows comments from Federal Reserve Chair Jerome Powell during a congressional hearing, where he acknowledged that the Fed is on high alert for possible retaliation from Iran in the form of cyberattacks. This comes after recent U.S. military strikes on Iranian nuclear sites, which have increased geopolitical tensions and heightened the risk of digital retaliation. 
Powell emphasized that cyber threats remain a major concern, stating that no institution can afford to be complacent because "the bad guys are always getting better."
Past Iranian cyber operations have targeted U.S. financial infrastructure and government agencies are once again warning institutions to be prepared. The financial sector, in particular, is seen as a likely target, making firms like CrowdStrike more central to national and corporate defense strategies.
The rising threat level has drawn attention back to CrowdStrike and its peers, which are viewed as critical providers of advanced digital security in volatile geopolitical environments. A brief investor relations update from CrowdStrike earlier this week also highlighted ongoing expansion in enterprise partnerships.
CRWD Price Action: Crowdstrike shares were up 1.51% at $492.69 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46100531/trump-nato-nvidia-chipmakers-nasdaq-record-high">Tech Stocks Notch New Highs As Chipmakers Power The Rally: What&#8217;s Driving Markets Wednesday?</a></li>
</ul>
Image Via Shutterstock.

News

Movers

CRWD

What's Going On With CrowdStrike Shares Today?

Shares of Nano Labs Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) are pulling back sharply Wednesday afternoon, a day after soaring on news of a major strategic shift towards the BNB cryptocurrency.
What To Know: The China-based Web 3.0 company announced on Tuesday a private placement agreement to raise up to $500 million through convertible senior notes to fund its new &#8220;<a href="https://www.benzinga.com/trading-ideas/movers/25/06/46075770/nano-labs-stock-is-soaring-tuesday-whats-going-on">BNB treasury strategy</a>.&#8221;
The initial announcement sent the stock climbing. Nano Labs revealed its ambitious plan to acquire $1 billion worth of BNB, the native cryptocurrency of the Binance chain, with a long-term goal of holding 5% to 10% of its total circulating supply. 
This move marks a significant expansion of its digital asset holdings, which previously focused on Bitcoin. The convertible notes have a 360-day maturity and an initial conversion price of $20 per ordinary share.
What Else: In a Form 6-K filing with the SEC on Wednesday, Nano Labs provided additional clarity. The company disclosed that the <a href="https://ir.nano.cn/static-files/b6a31ef3-c2ac-422f-b345-f1c405ad90ff">$500 million</a> fundraise may occur in multiple tranches.
An initial closing has already taken place, with the company issuing two notes for a total of 600 Bitcoins, valued at approximately $63.6 million. This brings the company&#8217;s total Bitcoin holdings to 1,000. The filing also stipulated that note repayments are to be made in Bitcoin.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, NA shares are trading lower by 20.3% to $11.83 Wednesday afternoon. NA has a 52-week high of $31.48 and a 52-week low of $2.75.
Read Also: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46098980/exclusive-bitcoin-is-hives-war-chest-who-needs-bankers">EXCLUSIVE: Bitcoin Is HIVE&#8217;s War Chest &#8211; Who Needs Bankers?</a>
<h2 class="wp-block-heading">How To Buy NA Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Nano Labs&#8217; case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

Nano Labs Stock Is Getting Hammered Wednesday: What's Going On?

WIIM

PONY

PONY stock has given up its prior gain. Pony AI shares were trading higher after the company announced it has been added to the Nasdaq Golden Dragon China Index.

COIN

Coinbase shares are trading higher after Bernstein maintained an Outperform rating and raised its price target from $310 to $510.

The <a href="https://www.benzinga.com/topic/fda-0">U.S. Food and Drug Administration</a> (FDA) is aware that Medtronic Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) and its subsidiary, Given Imaging Inc., have issued two letters to affected customers recommending that certain Bravo CF Capsule Delivery Devices be removed from where they are used and sold.
What Happened: Earlier in June, Medtronic <a target="_blank" href="https://www.fda.gov/medical-devices/medical-device-recalls/early-alert-esophageal-ph-monitoring-capsule-issue-medtronic" rel="noreferrer noopener">sent</a> all affected customers an "URGENT: MEDICAL DEVICE RECALL" letter. An updated letter was sent on June 16.
Medtronic on Tuesday stated that the capsule may not attach to the patient's esophagus or detach from the delivery device as intended due to a misapplication of the adhesive during manufacturing the Bravo CF capsule delivery device.
Risks associated with this issue include patient aspiration/inhalation, perforation of the esophagus, airway obstruction, hemorrhage/blood loss/bleeding, laceration of the esophagus, a delay in diagnosis, and foreign bodies remaining in the patient.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45932090/limited-impact-on-intuitive-surgical-from-reprocessed-robotic-instruments-analyst" rel="noreferrer noopener">Limited Impact On Intuitive Surgical From Reprocessed Robotic Instruments: Analyst</a>
Why It Matters: Medtronic has reported 33 serious injuries and no deaths associated with this issue.
The Bravo system is designed to place and attach a pH monitoring capsule to the esophagus, recording pH data to assist a physician in diagnosing clinical gastroesophageal reflux.
The Bravo system involves placing a pH capsule against the mucosal wall of the esophagus, simultaneously measuring pH, and transmitting the data to a recorder attached to the patient's waist.
The patient interacts with the recorder to indicate symptoms, allowing the physician to compare the patients' symptoms to the occurrence of the reflux episodes.
Additionally, on Monday, the FDA <a target="_blank" href="https://www.fda.gov/medical-devices/medical-device-recalls/medical-procedure-kits-correction-medline-industries-lp-issues-correction-medline-procedure-kits" rel="noreferrer noopener">said</a> that Medtronic&#8217;s subsidiary, Medline Industries, LP, sent all affected customers an Immediate Action Required Medical Device Recall notice in February.
Medline Industries LP is correcting certain lots of their medical procedure kits containing recalled Medtronic Aortic Root Cannulas due to the potential for excess material in the male luer. 
Medline is providing a sticker to attach to the procedure kits, notifying the user not to use the aortic root cannula within the procedure kit and to use an aortic root cannula from another supplier.
The use of the affected products may cause serious adverse health consequences, including procedure delay, neurological deficits/stroke (reversable and irreversible), and death. &nbsp;&nbsp;
&nbsp;At this time, Medline Industries has reported no serious injuries or deaths related to this issue.
Medline medical procedure kits containing Medtronic Aortic Root Cannulas are convenience kits used for various medical procedures.
The Medtronic Aortic Root Cannula in the kit is used for six hours or less during surgery with the heart-and-lung machine (cardiopulmonary bypass). The cannula may also be used to remove air from the major artery (aorta) when a bypass procedure is finished.
Price Action: MDT stock is up 0.3% at $86.36 at the last check on Wednesday
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/06/46098062/paychex-stock-takes-a-hit-as-margin-squeeze-overshadows-outlook" target="_blank" rel="noreferrer noopener">Paychex Stock Takes A Hit As Margin Squeeze Overshadows Outlook</a></li>
</ul>
Photo: Shutterstock

Large Cap

Health Care

General

FDA Sounds Alarm After 33 Injuries Tied To Medtronic Device Malfunction

It's already been an eventful week for U.S. markets, with tensions in the Middle East bubbling and then calming down following a <a href="https://www.benzinga.com/news/politics/25/06/46042703/iran-calls-us-bombing-of-nuclear-sites-very-very-dangerous-for-everybody">weekend of bombardment.</a> But despite the uncertainty regarding a potential ceasefire, the stock and commodities markets shrugged it off with the NASDAQ 100 finally notching a new all-time high and oil prices dipping back under $66 per barrel.
Markets are not out of the woods yet, as consumer sentiment continues to be shaky and the Fed remains on hold awaiting more economic data on the impact of tariffs. But the trend toward new all-time highs appears strong and retail traders are back to being bullish.
<h2 class="wp-block-heading">July 4th Sale: Save Up To $1,200 On Benzinga Pro</h2>
Your current setup is costing you money, whether it's free or expensive. Scattered tools mean missed opportunities. Consolidate everything into one powerful platform that actually works together. Stop missing opportunities. Sign up <a href="https://www.benzinga.com/pro/register/4th-of-july-sale/?utm_campaign=bzpro-4th&amp;el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_adType=SponsorAd&amp;utm_ad=RD062625">HERE</a> for Benzinga Pro at 60% off. 
Each of the five stocks rates highly on Benzinga Edge's Value Score rankings and exhibits technical signals indicating that momentum shifts may be brewing beneath the surface.
<h2 class="wp-block-heading">Costamare Inc.&nbsp;</h2>
Benzinga Edge Value Score: 98.04
Bulk shippers like Costamare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMRE#NYSE">CMRE</a>) have been caught in the Trump administration's tariff tug-of-war, but the decline has been so steep that the stock now appears undervalued. Despite a Q1 2025 earnings beat on both EPS and revenue, CMRE trades at just 3.7 times earnings and 0.5 times sales, and the dividend now yields over 5%.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXepogNA3oub0pkCTAE-Z1tJik259Dyf1zUxOYl00I0O1bb-228WkeiN_0bLeOw-H58rgG6TCAGG648vqj8Vbhxk-BLL23pBWuZ2A1gjIy6pLmgml2JBiLIoJ1dimfcwCPqqFeotng?key=hP5zZ9dGchmBHAd5CwfA1Q" alt="" /></figure>
CMRE spent most of the last 12 months in a prolonged downtrend. The stock peaked at $12.75 in June 2024 before dropping nearly 50%, with frequent false signals when the Relative Strength Index (RSI) tripped the Oversold alarm.&nbsp; But the stock rallied after the market bottom that followed Trump's reciprocal tariff announcement, gaining 10% and finally breaking through the long-term resistance level that had been in place for nearly a year. The RSI anticipated the breakout and actually triggered an Overbought signal twice in May and June, but now that it's back below 70, the new uptrend can continue.
<h2 class="wp-block-heading">Peabody Energy Corp.&nbsp;</h2>
Benzinga Edge Value Score: 98.08
Coal miners have also struggled in 2025 despite reassurances from the Trump administration. Small caps like Peabody (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTU#NYSE">BTU</a>) ($1.54 billion market cap) have been trending downward since Election Day. But BTU now trades at just 5 times forward earnings and 0.4 times sales, but its terrible start to 2025 (down 40% year-to-date) could be about to change. 
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXfX88YZ1zVqX8S0ODVvGaIsbqlVMPbJVvQwyRuFdNFUxuE1_GwHNMv2wqPlCrEFp1AtWvhErPuUtfKjbjMpBBfPjkFcmx5Rj_5vepvdoj2-354hA0QxQC-bDTycZw4Om8r0T3JI?key=hP5zZ9dGchmBHAd5CwfA1Q" alt="" /></figure>
Peabody's stock didn't experience a lengthy drawdown like CMRE, but the decline's brevity didn't mask its fierceness. The stock dropped more than 60% from Election Day to Easter, trading in a tight range with multiple failed attempts to breach support and resistance levels. The downtrend finally broke in April, and although the stock hasn't exactly gone parabolic, the breakout was confirmed by a bullish MACD crossover in May. The climb back to new highs might be a slow one, but BTU has an attractive valuation and a chart signaling the momentum has turned. It also still has a short interest of over 17%, which could further fuel any rallies in the coming days or weeks.
<h2 class="wp-block-heading">Hello Group Inc.&nbsp;</h2>
Benzinga Edge Value Score: 97.31
Hello Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOMO#NASDAQ">MOMO</a>) was a meme stock before there were meme stocks; its chart from 2017 and 2018 is enough to give even seasoned investors vertigo. But those days are long gone, and the stock has spent years trying to break out of a fortress-like resistance level. However, now that the stock trades at just eight times earnings and 0.7 times sales, investors are giving it a second look, and that resistance level has finally been broken.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXeqIMYt2D-5FPmnHZ_uycJYfVUM6YpwpfWPBVAv55Si8bSEmdGYFnbMmICjgpqFm7N9CyeylBor1Kg7qXSU3iNJvqpHfMR-rpui8p9nzZl0jTmylGY-Px19kB0_Og03AKpJcVT1Tw?key=hP5zZ9dGchmBHAd5CwfA1Q" alt="" /></figure>
Talk about lengthy range-bound trading, Hello Group has traded between $5 and $8 since September 2023, and has failed multiple attempts to break through the resistance level above the $8 mark. But the MACD is showing outsized bullish momentum compared to previous quarters. The share price finally crested $8.15 for the first time in nearly two years. Volatility is increasing (did you expect something different with the ticker MOMO?), but if the old resistance level becomes support, this stock might not be done posting explosive gains in 2025.
<h2 class="wp-block-heading">Hamilton Insurance Group Ltd.&nbsp;</h2>
Benzinga Edge Value Score: 95.46
Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HG#NYSE">HG</a>), a small-cap insurer based in Bermuda, has a market capitalization of $2.15 billion and annual sales of $2.3 billion. Strong earnings and guidance raises have fueled the stock's recent upward move, as the company handily beat EPS (0.48 per share vs. the expected 0.04) and revenue estimates ($843 million vs. the expected $498 million). But despite this massive beat, the stock still trades at just 5 times forward earnings and 0.9 times sales. 
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXfpPbi5r2etuPt1EIIZowVx3H4uW2WOWxCi8fU0PFtBA9UG1fwnOpVci1FucqSDMPc-9yfRD9qvdOuBlp5tNDwJNuNnNYYGA5vn9utbV2AX4LP6GcvvbkMU4bmrkkqkBeTFPTSzPw?key=hP5zZ9dGchmBHAd5CwfA1Q" alt="" /></figure>
Above is a chart showing an undervalued company poised to build a new bull market. The stock price has been trading above both the 50-day and 200-day MAs, with the 50-day MA acting as support since mid-2024. Trump's tariffs briefly interrupted this trend, but the price quickly rose back above both MAs and appears to be balancing along the 50-day once again. The RSI is also back under 60 after a brief venture into Overbought territory, so another bounce off the 50-day would likely have strong upside momentum.
<h2 class="wp-block-heading">Tri-Pointe Homes Inc.&nbsp;</h2>
Benzinga Edge Value Score: 95.14
Investing in homebuilders is a dicey proposition at the moment, considering the headwinds facing the construction industry. However, Tri-Pointe's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPH#NYSE">TPH</a>) surprisingly strong Q1 2025 earnings indicate a resilient company capable of weathering economic turbulence. TPH posted EPS figures of $0.70 per share, easily exceeding the $0.45 per share estimate. The April report also triggered a momentum shift in the stock, which currently trades at just 8.9 times forward earnings and 0.65 times sales.
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXeDNgKBM88C12hDZmnsVLwopEb16MbGlyPNMOyDcylqxqTQWvF_bLukcvCnDXwF6O4NXh1gpzT4GWBJ6m31JGOwgYSg4-Ao8sf8ytTSwfcNKN4QsfphbXe46Qnj6CAbuq54dapFhQ?key=hP5zZ9dGchmBHAd5CwfA1Q" alt="" /></figure>
Like most homebuilders, TPH's shares couldn't shake downward momentum as high mortgage rates kept the housing market frozen. Housing is still struggling to gain traction (highlighted by this week's <a href="https://www.benzinga.com/news/macro-notification/25/06/46070420/us-home-sales-sink-to-slowest-may-since-2009-as-mortgage-rates-and-record-prices-keep-buyers-on-the-sidelines">poor report</a> in new home sales), but TPH has finally broken its downtrend, and momentum is slowly consolidating at a new support level. The RSI has been trending upward in unison with the stock price, giving more weight to the momentum shift. And with the RSI sitting at 57, the upswing likely has more room to run.
Editorial content from our expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

Small Cap

Opinion

Trading Ideas

CMRE

MOMO

5 Undervalued Small Caps Showing Signs Of Breaking Out

FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) shares are moving lower Wednesday after the company issued soft guidance for the first quarter. Multiple analysts also cut price targets following the company&#8217;s <a href="https://www.benzinga.com/markets/earnings/25/06/46083842/fedex-q4-earnings-revenue-eps-beat-estimates-shares-slide-on-soft-guidance">fourth-quarter results</a>.
Q4 Details: FedEx reported adjusted earnings per share of $6.07, beating the consensus estimate of $5.87. In addition, the company reported sales of $22.20 billion, beating the consensus estimate of $21.83 billion.
Q1 Outlook: FedEx sees adjusted earnings per share of $3.40 to $4.00, versus the consensus estimate of $4.15.
Competitor United Parcel Service Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) may also be trading lower in sympathy with FedEx, as investors view the soft guidance as a potential sign of broader industry challenges. UPS isn&#8217;t due to report earnings until next month.
Analyst Changes: Following the earnings report, multiple analysts issued <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/quote/FDX/analyst-ratings&amp;ved=2ahUKEwjAlaWEhY2OAxUJFFkFHY2EFcMQFnoECBgQAQ&amp;usg=AOvVaw0NWQwtY68qb5CbFcDU6hyi">price target adjustments</a>.
<ul class="wp-block-list">
<li>Citigroup analyst Ariel Rosa maintained a Buy rating on FedEx and lowered the price target from&nbsp;$267&nbsp;to&nbsp;$259.</li>
<li>TD Cowen analyst Jason Seidl maintained a Buy rating on FedEx and lowered the price target from&nbsp;$310&nbsp;to&nbsp;$269.</li>
<li>Stifel analyst J. Bruce Chan maintained a Buy rating on FedEx and lowered the price target from&nbsp;$329&nbsp;to&nbsp;$315.</li>
<li>Susquehanna analyst Bascome Majors maintained a Positive rating on FedEx and raised the price target from&nbsp;$290&nbsp;to&nbsp;$295.</li>
<li>UBS analyst Thomas Wadewitz maintained a Buy rating on FedEx and lowered the price target from&nbsp;$311&nbsp;to&nbsp;$297.</li>
</ul>
See Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46099726/super-micro-computer-smci-stock-is-surging-today-whats-going-on">Super Micro Computer (SMCI) Stock Is Surging Today: What&#8217;s Going On?</a>
FDX Price Action: At the time of publication, FedEx Stock was down 3.41% at $221.70, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwjv3bfFho2OAxWnEFkFHankK0oQFnoECCkQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>.
Image via Shutterstock.

FedEx Stock Is Trading Lower Wednesday: What's Going On?

<a href="https://www.sec.gov/Archives/edgar/data/1946703/000121390025057745/ea0246681-f1_webuy.htm">https://www.sec.gov/Archives/edgar/data/1946703/000121390025057745/ea0246681-f1_webuy.htm</a>

Offerings

WBUY

Webuy Global Files For Offering Of 1M Class A Ordinary Shares And/Or Pre-Funded Warrants To Purchase Class A Ordinary Shares

Once a symbol of financial catastrophe, subprime consumers are now showing signs of resilience and spending power that defy economic uncertainties, according to Goldman Sachs, with the bank highlighting several investment opportunities tied to <a href="https://www.benzinga.com/analyst-ratings/analyst-color">the lower-income group. </a>
In a note issued Wednesday, Goldman Sachs analysts led by George K. Tong said U.S. subprime consumers—typically defined as individuals with credit scores below 660—are holding up better than expected despite economic headwinds such as tariffs, inflation and high interest rates.
<h3 class="wp-block-heading">US Subprime Consumers Are Stronger Than You Think</h3>
"Our call is that subprime consumers are, and will remain, resilient, with positive spending growth and improving delinquency trends despite economic uncertainty," Tong said.
Consumer wealth in the bottom income quintile rose 7% year-over-year through May 2025. The labor market remains reasonably healthy, with unemployment at 4.2% in May, while debt service payments as a share of disposable income came in at 11.3%, below the 45-year average of 11.9%.
Household debt stood at 61% of nominal GDP in 2024, the lowest level since late 1999 and significantly under the 20-year average of 70%, suggesting consumers remain financially unburdened.
Goldman said subprime borrowers are actively adjusting their financial behavior by shifting away from discretionary and high-cost items, instead prioritizing essential purchases such as groceries, household goods and lower-cost alternatives. 
This disciplined approach to spending reflects a prudent response to economic uncertainty—not distress.
<h3 class="wp-block-heading">Subprime Credit Metrics Show Positive Signs</h3>
Recent data shows a broad improvement in credit health across cards, auto loans and personal loans, suggesting that subprime consumers are stabilizing their financial positions. 
Thirty-plus day card delinquencies among lower-income borrowers fell 0.23% year-over-year in the first quarter of 2025 to 4.5%, marking a key reversal after a prolonged period of rising late payments. 
Deep subprime 60-plus day card delinquencies declined to 25.46% in May 2025, down from 27.42% a year earlier, the first sustained drop since late 2022.
In the auto segment, 60-plus day delinquencies among deep subprime borrowers slipped to 7.75% in May, now falling below the five-year average of 7.80%. This marks a turning point after nearly two years of worsening trends. 
Similarly, deep subprime personal loan delinquencies fell from 15.27% to 14.25% in May, extending the string of year-over-year improvements that began in mid-2024. 
Mortgages remain the only category showing slight deterioration, with deep subprime 90-plus day delinquencies rising to 12.92% in May, up from 11.59% a year ago, slightly above the five-year average of 12.88%. 
Yet, the investment bank notes that overall mortgage delinquency remains exceptionally low at just 0.7% of outstanding balances, reflecting the relative health of the broader housing market.
<h3 class="wp-block-heading">Subprime Crisis? Not This Time – 8 Stocks To Watch</h3>
Goldman Sachs recommends eight stocks across various sectors that are well-positioned to benefit from this subprime resurgence:
<ol class="wp-block-list">
<li>Fair Isaac Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NASDAQ">FICO</a>) – Buy-rated, $2,244 price target With improving delinquency trends, FICO could see a pickup in credit originations and score inquiries.</li>
<li>Dollar Tree Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) – Buy-rated, $94 PT Budget-focused consumers are helping drive growth, especially as DLTR boosts operational efficiency.</li>
<li>Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) – Buy-rated, $190 PT Steady demand for non-discretionary tobacco and ZYN products fuels growth, even in low-income segments.</li>
<li>Monster Beverage Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>) – Buy-rated, $72 PT Energy drinks remain an affordable indulgence for subprime consumers, supporting revenue and margin expansion.</li>
<li>Affirm Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) – Buy-rated, $58 PT As a leading Buy Now, Pay Later provider, AFRM is gaining from better credit and growing demand.</li>
<li>Block Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) – Buy-rated, $57 PT Block's Cash App and lending business is rebounding, supported by subprime borrower stability.</li>
<li>Capital One Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) – Buy-rated, $242 PT Credit card and auto segments are seeing improving delinquency trends and potential reserve releases.</li>
<li>Synchrony Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>) – Buy-rated, $70 PT With 28% of loans to subprime consumers, SYF is poised to benefit from improving net charge-off and delinquency data.</li>
</ol>
Read now:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46096528/nasdaq-100-record-highs-rally-historical-performance">Nasdaq 100 Hits Record Highs After 30% Rally: History Suggests It&#8217;s Not Done Yet</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Equities

Mid Cap

Econ #s

Economics

Analyst Ratings

AFRM

DLTR

FICO

MNST

Subprime Was A Trainwreck In 2008―Now It's A Sweet Spot, Says Goldman Sachs

Molson Coors Beverage Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) is quiet on Wednesday. After <a href="https://www.benzinga.com/content/46043294/these-3-consumer-staple-giants-are-oversold-and-set-to-skyrocket">a long downtrend</a>, the shares have consolidated over the past few days and found support around the $48 level.
They are also very oversold and may be starting to reverse. This is why it is our Stock of the Day.
Stocks that are oversold and drop to support tend to rebound and rally. As you can see on the chart, this happened when Molson found support around the $52.50 level in January and early May.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="591" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25151948/TAP-1024x591.png" alt="" class="wp-image-962168" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25151948/TAP-1024x591.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25151948/TAP-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25151948/TAP-768x443.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25151948/TAP.png 1410w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Oversold refers to a stock's momentum. Most of the time, a stock is within its typical trading range. If aggressive and emotional sellers push the price below this range, traders will say the stock is oversold.
Read Also: <a href="https://www.benzinga.com/markets/tech/25/06/46096528/nasdaq-100-record-highs-rally-historical-performance">Nasdaq 100 Hits Record Highs After 30% Rally: History Suggests It&#8217;s Not Done Yet</a>
This is an important dynamic.
It will draw buyers into the market. Many strategies are based on the concept of reversion to the mean, and these buyers will be anticipating a move higher. Their buying could put upward pressure on Molson.
The stock is also at a support level.
Support is a level or narrow price range with a large amount of buying interest. If a stock is trending lower, it is due to the lack of demand or a limited number of buyers. But at support levels, there is enough demand to absorb the supply.
This is why selloffs end or pause at support. &nbsp;
Molson has found support at around $48.30. This level was also support in August.
Some of the traders who sold their shares then came to believe they had made a mistake when the price headed higher. Some vowed to repurchase their shares at their selling prices if they could ever do so.
So, when the stock recently dropped back to this price, these remorseful sellers placed buy orders. The large concentration of these orders caused support to form at the level again.
This combination of being at a level where there is a large amount of buy interest in addition to being oversold could be a bullish setup. Molson may be about to rally.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/46094069/iran-breaks-silence-says-nuclear-facilities-badly-damaged-by-us-strikes">Iran Breaks Silence, Says Nuclear Facilities &#8216;Badly Damaged&#8217; By US Strikes</a></li>
</ul>
Photo: Shutterstock

Technicals

Stock Of the Day: Will Molson Coors Finally Reverse?

<a href="https://www.cnbc.com/2025/06/25/southwest-airport-lounges-europe-flights-ceo-bob-jordan.html">https://www.cnbc.com/2025/06/25/southwest-airport-lounges-europe-flights-ceo-bob-jordan.html</a>

'Southwest Airport Lounges? CEO Says Carrier Is Open To Even More High-End Changes'- CNBC

Bitcoin Cash (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bch/usd">BCH</a>) is soaring higher during midday trading on Wednesday, with its price climbing around 6.30% to $482.62. Here&#8217;s what investors <a href="https://www.benzinga.com/crypto">need to know</a>.
What To Know: The upward momentum for BCH Wednesday is not happening in isolation. The wider crypto market is showing renewed strength, fueled by optimism over a potential Federal Reserve rate cut, supportive legislative news and sustained institutional buying.
During his <a href="https://www.benzinga.com/markets/equities/25/06/46100531/trump-nato-nvidia-chipmakers-nasdaq-record-high">second day</a> of congressional testimony, Federal Reserve Chair Jerome Powell linked potential interest rate cuts to evolving trade conditions. While offering no specific timeline, he suggested that future trade agreements could create the flexibility needed to lower rates.
Read Also: <a href="https://www.benzinga.com/money/how-to-buy-bitcoin-cash">How To Buy Bitcoin Cash</a>
Major assets like Solana also posted <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46091840/bitcoin-ethereum-xrp-dogecoin-hold-gains">strong gains</a> of 6%, while market leader Bitcoin traded 1.2% higher, surpassing the $107,000 mark. The collective rally across tech and crypto Wednesday likely indicates renewed investor confidence as positive macroeconomic and industry-specific developments drive assets higher across the board.
What Else: For investors, Bitcoin Cash is a cryptocurrency that spun off from the original Bitcoin in 2017. It was created to serve as a more efficient system for everyday transactions.
By increasing the block size of its blockchain, Bitcoin Cash aims to process payments faster and with lower fees than its predecessor, positioning itself as a form of &#8220;peer-to-peer electronic cash.&#8221;
Read Also: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46101110/bitcoin-senator-cynthia-lummis-lauds-white-houses-real-enthusiasm-for-crypto-legislation">&#8216;Bitcoin Senator&#8217; Cynthia Lummis Lauds White House&#8217;s &#8216;Real Enthusiasm&#8217; For Crypto Legislation</a>

$BCH

What's Going On With Bitcoin Cash Wednesday?

CoreWeave, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) shares are trading lower on Wednesday. HC Wainwright &amp; Co. initiated coverage on the stock with<a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/06/46097418/coreweave-ipo-was-fantastic-entry-point-but-stock-now-a-little-overheated"> a Neutral rating</a>.
What To Know: Despite several positive points, HC Wainwright &amp; Co. analyst Kevin Dede said on Wednesday that the stock may need a "minute to breathe" after soaring fivefold, compared to a 25% gain in the Nasdaq over the same period.
Some of the analyst's bullish points include CoreWeave's early deployment of Nvidia's GB200 chips, giving it a first-mover edge in AI infrastructure. The company has also secured long-term contracts with major customers like OpenAI, Microsoft and Meta, offering strong revenue visibility.
The analyst added that CoreWeave is positioned to benefit from a fast-growing AI and software market, which could boost performance and help retain customers.
On the other hand, Dede flagged several risks, including CoreWeave's heavy capital needs. Furthermore, the company has outlined a $20 to $23 billion capex plan this year, which may require taking on more debt or selling additional stock.
Additionally, the analyst pointed to execution risks tied to CoreWeave's data center partners, noting that delays or supply chain issues could make it harder for the company to meet customer obligations.
See Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46101268/the-metals-company-tmc-stock-is-climbing-wednesday-whats-going-on">The Metals Company (TMC) Stock Is Climbing Wednesday: What&#8217;s Going On?</a>
CRWV Price Action: At the time of publication, CoreWeave stock was down 6.57% at $161.32, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwj_6pDhk42OAxWjhIkEHaySERAQFnoECCQQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>.
Image via Shutterstock.

CRWV

CoreWeave Stock Is Moving Lower Wednesday: What's Going On?

Personalized medicine, which involves tailoring treatment to a patient&#8217;s unique disease profile, is widely regarded as the holy grail of medicine. However, the current implementation of this approach faces significant hurdles.
Bank of America Securities (BofA) highlights that the precision medicine approach is currently <a target="_blank" href="https://www.benzinga.com/topic/artificial-intelligence" rel="noreferrer noopener">cost, labor, and time-intensive</a>.
Analysts Alec Stranahan and Michael Ryskin specifically point out that the substantial amount of manual work involved in processing complex biological data and making treatment decisions leads to considerable delays.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/06/45820489/goldman-sachs-bullish-on-branded-drug-upside-at-teva-what-about-viatris" rel="noreferrer noopener">Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?</a>
Beyond the practical challenges, precision medicine also grapples with data validation issues. Given the infinitely complex nature of biology and the huge number of interactions between biological systems, researchers often run into issues with validating the impact of genes/pathways associated with disease progression/response to treatment.
Despite these inherent challenges, the integration of Artificial Intelligence (AI) and Machine Learning (ML) is widely recognized as a pivotal enabler for advancing precision medicine.
Consequently, a number of companies are actively leveraging these technologies to innovate within the precision medicine landscape, striving to make tailored treatments more accessible, efficient, and effective.
These companies include Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>), Exact Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>), Quest Diagnostics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>), and LabCorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), each employing AI in unique ways to enhance diagnostics, therapy selection, and overall patient care across the care continuum.
<h2 class="wp-block-heading">Tempus AI</h2>
BofA analyst says Tempus AI perfectly fits the theme of <a target="_blank" href="https://www.benzinga.com/news/movers-shakers/25/06/45726456/tempus-ai-stock-is-surging-today-what-investors-are-watching" rel="noreferrer noopener">AI in precision medicine</a>.
Like most MDx companies, Tempus AI has built its business off an industry-leading database of clinico-genomic data. Tempus leverages this data by training AI/ML algorithms to parse through the data and detect patterns and anomalies.&nbsp;&nbsp;
BofA reiterates a Neutral rating for Tempus AI, given its already premium valuation. The analyst remains constructive on the business and key markets. However, due to peer group expansion, BofA raised its price <a target="_blank" href="https://www.benzinga.com/quote/TEM/analyst-ratings" rel="noreferrer noopener">forecast from $68 to $70</a>.
<h2 class="wp-block-heading">Guardant Health</h2>
Guardant Health was an early mover in the liquid biopsy cancer testing/therapy selection market with their <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/45756387/why-is-cancer-diagnostic-guardant-health-stock-trading-higher-on-tuesday" rel="noreferrer noopener">Guardant 360 (G360) test</a>.
Guardant Health has a clear goal to build upon its G360 test (therapy selection) and expand across the care continuum, thus allowing it to participate in a patient&#8217;s receiving precision medicine at all stages post-cancer diagnosis.
Guardant Health has its business built on the algorithms that it runs.
BofA <a target="_blank" href="https://www.benzinga.com/quote/GH/analyst-ratings" rel="noreferrer noopener">maintains a Buy rating</a> on Guardant Health, given its leading position, strong growth profile, and upcoming catalyst path for new products.
<h2 class="wp-block-heading">Exact Sciences</h2>
BofA analysts say Exact Sciences Corp. has expanded to offer services <a href="https://www.benzinga.com/general/health-care/25/05/45165534/cancer-diagnostic-firm-exact-sciences-ceo-says-strong-q1-paves-way-for-transformative-2025-lifts-annual-guidance" target="_blank" rel="noreferrer noopener">across the care continuum</a>.
While Exact Sciences started screening for colorectal cancer specifically, their focus has been steered towards all indications and across the treatment paradigm.
Exact Sciences&#8217; legacy Cologuard test / early detection doesn&#8217;t necessarily &#8220;fit&#8221; the precision medicine theme; however, everything Exact has done since is &#8220;precision medicine / AI-aligned,&#8221; BofA added in its investor note on Wednesday.
Given its strong financial profile and near-term catalyst path, the analyst maintains a <a target="_blank" href="https://www.benzinga.com/quote/EXAS/analyst-ratings" rel="noreferrer noopener">Buy rating on Exact Sciences</a>.
<h2 class="wp-block-heading">NeoGenomics</h2>
NeoGenomics has been known as a traditional reference lab offering many hotspot tests. However, by adding the PanTracer testing family and data services offering, NeoGenomics leverages the numerous hotspot data points and can build those into a more robust AI algorithm to inform the more modern therapy selection tests.
The dataset/algorithm and 500+ tests create a flywheel where the tests that are sold generate information. The information informs the algorithm, eventually leading to more accurate algorithms, which help market the tests… bring you back to more tests.
BofA <a target="_blank" href="https://www.benzinga.com/quote/NEO/analyst-ratings" rel="noreferrer noopener">maintains a Neutral rating</a> on NeoGenomics given near-term headwinds and more limited upside versus its prior trajectory.
<h2 class="wp-block-heading">Quest Diagnostics</h2>
Quest Diagnostics is showing trends toward AI in precision medicine with <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44929366/quest-diagnostics-revenue-rebound-strategic-moves-fuel-outlook-confidence" rel="noreferrer noopener">Haystack and PathAI Quest</a>.
While not traditionally considered a &#8220;leader&#8221; in AI/precision medicine, Quest Diagnostics has shown progress toward becoming a company to watch.
At DGX&#8217;s 2025 Investor Day, management discussed innovations in lab diagnostics, including the adoption of AI and automation. Given Quest Diagnostics&#8217; strong, steady performance and lower exposure to macro/policy overhangs, the analyst <a target="_blank" href="https://www.benzinga.com/quote/DGX/analyst-ratings" rel="noreferrer noopener">maintains a Buy rating</a>.
<h2 class="wp-block-heading">LabCorp</h2>
LabCorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) aims to be a notable player in AI precision medicine. Although LabCorp is known as a traditional reference lab, with trends toward AI and precision medicine, LH has shown signs of <a target="_blank" href="https://www.benzinga.com/25/02/43539754/labcorp-reports-q4-earnings-beat-and-expects-strong-2025-growth-analyst-reiterates-outperform-on-stable-2025-outlook" rel="noreferrer noopener">jumping on the bandwagon</a>.
While LabCorp already offers NGS tests, there appears to be a clear trend and focus towards advancing its AI/precision medicine portfolio.
BofA <a target="_blank" href="https://www.benzinga.com/quote/LH/analyst-ratings" rel="noreferrer noopener">maintains a Buy rating</a> on LabCorp, given strong and steady performance and lower exposure to macro/policy overhangs.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/46100456/tesla-robotaxi-scaling-growth-will-be-slow-in-near-term-goldman-sachs" target="_blank" rel="noreferrer noopener">Tesla Robotaxi Scaling Growth Will Be Slow In Near Term: Goldman Sachs</a></li>
</ul>
Photo by Piotr Swat via Shutterstock

Biotech

EXAS

Laboratory Corporation Of America Holdings

Could Personalized Medicine Be Your Portfolio's Next Big Winner? Find Out

<a href="https://breakingdefense.com/2025/06/boeing-hires-former-northrop-exec-to-lead-air-force-one-program/">https://breakingdefense.com/2025/06/boeing-hires-former-northrop-exec-to-lead-air-force-one-program/</a>

'Boeing Hires Former Northrop Exec To Lead Air Force One Program'- Breaking Defense

Robinhood Markets Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) stock is trending on Wednesday after hitting all-time highs. Here&#8217;s a look at what you <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46084249/robinhood-markets-hood-stock-hits-a-new-all-time-high-whats-going-on">need to know</a>.
What To Know: Robinhood is expected to provide an update on June trading metrics this week, according to the company&#8217;s investor relations site. Robinhood also held its annual shareholder meeting on Wednesday. 
The Robinhood website says the company is anticipated to release&nbsp;&#8220;month-to-date trading color&#8221; for June after the market close on Thursday. Earlier this month, the company provided early color on May operating data ahead of a presentation at the Piper Sandler Global Exchange &amp; Trading conference.
As of the end of May, Robinhood said it had 25.9 million funded accounts and $255 billion in platform assets, up 89% year-over-year. The company reported $3.5 billion in net deposits for the month and $59.1 billion in total deposits over the past year.
Equity trading volumes rose 108% to $180.5 billion, while options contracts increased 36% to 179.8 million. Crypto volumes were also up 65% to $11.7 billion last month.
Robinhood may also be getting a boost in recent trading sessions after a director disclosed the purchase of nearly $2 million in common stock, the first insider buy reported in several years, according to Benzinga&#8217;s Insider Trades <a href="https://www.benzinga.com/quote/HOOD/insider-trades">data</a>. 
Recent analyst updates suggest analysts are turning more bullish with Mizuho maintaining an Outperform rating and raising its price target to $80 last week. Goldman Sachs also reiterated a Buy rating earlier this month and raised its target to $82 and Deutsche Bank lifted its target to $85.
Robinhood CEO Vlad Tenev said on CNBC this week that retail investor activity has remained strong despite rising <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46097909/robinhood-ceo-highlights-retail-investor-interest-in-nvidia-tesla-despite-middle-east-tensions-barely-a-blip">geopolitical tensions in the Middle East</a>. He noted that while such events once triggered volatile overnight moves, current investor sentiment appears largely unaffected, with continued focus on growth stocks like Nvidia and Tesla, as well as crypto assets.
HOOD Price Action: Robinhood shares were up 0.44% at $82.37 at the time of writing. The stock hit another all-time high of $85.55 earlier in Wednesday&#8217;s trading session, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/46101160/why-is-nektar-therapeutics-stock-trading-higher-on-wednesday">Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?</a></li>
</ul>
Image: NRSPro/Shutterstock.

HOOD

What's Going On With Robinhood Stock Today?

Calamos Investments is refreshing the <a href="https://www.benzinga.com/etfs">income ETF turf</a> with the launch of Calamos Autocallable Income ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAIE#NYSE">CAIE</a>) on Wednesday. 
This fund aims to make one of Wall Street&#8217;s more esoteric structured products a liquid, accessible solution for investors.
In its essence, CAIE invests in a ladder portfolio of autocallable notes, which are structured securities that offer frequent coupons and can return principal, provided the underlying equity index does not drop below a specified barrier. 
The ETF aims for high, predictable monthly income and thus serve as a substitute for individuals wanting yields greater than those of regular fixed-income vehicles.
Also Read: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/06/46100785/not-enough-believers-faith-based-etf-folds-amid-industry-purge">Not Enough Believers: Faith-Based ETF Folds Amid Industry Purge</a>
The underlying index is the MerQube US Large-Cap Vol Advantage Index, and the auto callables will be designed to mature in five years, with a -40% coupon and maturity barrier. If the reference index experiences a gain, the notes will be automatically callable after a one-year non-call period. The fund will ladder more than 52 such notes, weekly staggered, to assist in mitigating timing risk and smoothing income.
Backing the fund is a heavy-hitting roster: J.P. Morgan is the lead swap counterparty, MerQube supplies the index, and Calamos oversees the portfolio. The ETF will have a 0.74% expense ratio and feature daily liquidity and tax-favored distributions, an unusual combination for such a strategy.
This action connects to a surging demand for defined income. 
Autocallable structured notes alone were issued for more than $104 billion in 2024, comprising over two-thirds of the structured products market. 
Derivative income funds, such as trendy covered-call ETFs, have seen net inflows totaling $39 billion, bringing the total assets under management to $114 billion.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/06/46098656/nvidia-amazon-tesla-among-tech-stocks-hedge-funds-are-piling-into-heres-how-etfs-like-ivv-spy-voo-are-riding-the-wave">Nvidia, Amazon, Tesla Among Tech Stocks Hedge Funds Are Piling Into — Here&#8217;s How ETFs Like IVV, SPY, VOO Are Riding The Wave</a></li>
</ul>
Image: Shutterstock

New ETFs

ETFs

CAIE

Calamos Unveils Callable-Note ETF For Predictable Payouts

<a href="https://www.statnews.com/2025/06/25/nih-halts-research-grant-terminations-email-shows/?utm_campaign=twitter_organic&amp;utm_medium=social&amp;utm_source=twitter">https://www.statnews.com/2025/06/25/nih-halts-research-grant-terminations-email-shows/?utm_campaign=twitter_organic&amp;utm_medium=social&amp;utm_source=twitter</a>

BRKR

ILMN

QTRX

'NIH halts grant terminations 'effective immediately,' email says'- Stat News

Providing a diverse range of perspectives from bullish to bearish, 15 analysts have published ratings on Honeywell Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) in the last three months.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $226.6, with a high estimate of $265.00 and a low estimate of $178.00. This current average has increased by 1.71% from the previous average price target of $222.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1750878092_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Honeywell Intl among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$226.00</td>
<td>$226.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$258.00</td>
<td>$243.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$265.00</td>
<td>$242.00</td>
</tr>
<tr>
<td>Brett Linzey</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$217.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Andrew Obin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$250.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$182.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$225.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$226.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$243.00</td>
<td>$247.00</td>
</tr>
<tr>
<td>Brett Linzey</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$235.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Andrew Obin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$229.00</td>
<td>$253.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$205.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$178.00</td>
<td>$205.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Honeywell Intl. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Honeywell Intl compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Honeywell Intl's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Honeywell Intl's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HON/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Honeywell Intl analyst ratings.</a>
<h2>Delving into Honeywell Intl's Background</h2>
Honeywell traces its roots to 1885 with Albert Butz's firm, Butz Thermo-Electric Regulator, which produced a predecessor to the modern thermostat. Other inventions by Honeywell include biodegradable detergent and autopilot. Today, Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. It operates through four business segments: aerospace technologies (37% of 2023 company revenue), industrial automation (29%), energy and sustainability solutions (17%), and building automation (17%). Recently, Honeywell has made several portfolio changes to focus on fewer end markets and align with a set of secular growth trends. The firm is working diligently to expand its installed base, deriving around 30% of its revenue from recurring aftermarket services.
<h3>Unraveling the Financial Story of Honeywell Intl</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining Honeywell Intl's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.87% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 14.75%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Honeywell Intl's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.03% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Honeywell Intl's ROA stands out, surpassing industry averages. With an impressive ROA of 1.93%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 1.88, Honeywell Intl adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

15 Analysts Assess Honeywell Intl: What You Need To Know

Across the recent three months, 17 analysts have shared their insights on Shake Shack (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $114.65, a high estimate of $145.00, and a low estimate of $85.00. This current average represents a 4.85% decrease from the previous average price target of $120.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1750878071_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Shake Shack's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Ivankoe</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Underweight</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Sara Senatore</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$134.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Anthony Trainor</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$115.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Andrew Charles</td>
<td>TD Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Jake Bartlett</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>John Ivankoe</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$100.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Brian Vaccaro</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$140.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>David Tarantino</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Andrew Charles</td>
<td>TD Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Dennis Geiger</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Jeffrey Bernstein</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Jake Bartlett</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$131.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Chris O'Cull</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$97.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Brian Bittner</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>David Tarantino</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Alton Stump</td>
<td>Loop Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$127.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Shake Shack. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Shake Shack compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Shake Shack's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Shake Shack's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SHAK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Shake Shack analyst ratings.</a>
<h2>About Shake Shack</h2>
Shake Shack Inc is a roadside burger stand. It serves a classic American menu of premium burgers, hot dogs, crispy chicken, frozen custard, crinkle-cut fries, shakes, beer, wine and more. The company's burgers are made with a whole-muscle blend of all-natural, hormone and antibiotic-free Angus beef, ground fresh daily, cooked to order, and served on a non-genetically modified organism (GMO) potato bun. Its menu focuses on food and beverages, crafted from a range of classic American foods. The company serves draft Root Beer, seasonal freshly-squeezed lemonade, organic fresh brewed iced tea, cold brew coffee, organic apple juice, and Shack20 bottled water.
<h3>Unraveling the Financial Story of Shake Shack</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Shake Shack's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 10.46%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Shake Shack's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 1.32%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Shake Shack's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.9%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Shake Shack's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.25%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Shake Shack's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.74.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Vital Healthcare Prop Tr

Vital Healthcare Prop Tr (VTHPF) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌